trusted by the life sciences industry

Trusted by the Life Sciences Industry

NASDAQ: CYRX April 2017 1

Safe Harbor – Forward Looking Statements

This presentation contains certain forward-looking statements that involve risks and

uncertainties. Such forward-looking statements include statements regarding attempts to

identify new strategic opportunities which may include a strategic transaction, plans

regarding partnering activities, product pricing, financial forecasts. Such statements are

only predictions and the Company's actual results may differ materially from those

anticipated in these forward-looking statements. Factors that may cause such differences

include the risk that the Company may not be able to identify acceptable strategic

opportunities or conclude any strategic transaction which it does identify, the risk that

products that appeared promising in early use do not demonstrate the same utility in

larger-scale uses, the risks associated with the Company's reliance on outside financing to

meet its capital requirements, and the risks associated with the Company's reliance on

collaborative partners for shipping. Forward-looking statements are inherently subject to

risks and uncertainties, some of which cannot be predicted, or quantified. Future events

and actual results could differ materially from those set forth in, contemplated by, or

underlying the forward-looking statements. The risks and uncertainties to which forward-

looking statements are subject include, but are not limited to, the effect of government

regulation, competition and other material risks. These factors and others are more fully

discussed in the Company's periodic reports and other filings with the Securities and

Exchange Commission.


Company Overview

Leading cryogenic logistics solutions for the life sciences industry

Advanced technologies, validated by life sciences clients, such as

Sanofi and Novartis

Selected to support 129 clinical trials in regenerative medicine;

including 23 of 28 top CAR-T programs

Industry’s only proprietary cryogenic shippers

with real-time condition monitoring

The cryogenic solution for FedEx, UPS and DHL

April 2017 3NASDAQ: CYRX

Strong and Growing Client Base

Biopharma

Reproductive

Medicine

Animal Health



Growth Trajectoryclin

ical tr

ials

Commercial StagePhase

I

Phase

II

Phase

III

Commercial

Stage

5853

18

2 Clients filed

BLA’s with FDA

in 2017

($15-75K) ($50-125K) ($100-250K) ($2M-20M)

* Revenue potential from clinical

to commercial

Primary Target Market: Regenerative Therapy

(a) Alliance for Regenerative Medicine.

(b) Market and Markets, 2016.

6April 2017NASDAQ: CYRX

Inflection point: Commercialization

expected to begin in 2017

Launch strategies require scalable

cryogenic logistics support

Cryoport is the only effective solution

on the market for regenerative therapy

logistics

6 BLAs for regenerative therapies

expected in 2017

Rapid growth is just beginning:

$49B regenerative market by 2021(b)

(a)

(192 in 2015)

(376 in 2015)

(63 in 2015)

The Science Behind Our Logistics Solutions

PACKAGING

CONDITION MONITORING

INFORMATION

TECHNOLOGY

LOGISTICS EXPERTISE


Knowhow behind our Cryoport Express ShippersTM

Engineered and validated for safe transport of

fragile biologics in dynamic shipping

conditions

SmartPak II™ Condition Monitoring System

monitors and records internal and external

temperatures, humidity, openings, orientation

and other vital information in real-time

Non-hazardous liquid nitrogen dry vapor

technology eliminates cellular degradation

Cryogenically stable temperature providing

10-day dynamic holding time and enabling

global reach

International Air Transport Association (IATA)

and International Safe Transit Association

(ISTA) certified


Validated. Safe. Effective. Efficient.

Real-time Monitoring


Interactive multi-layer graphics provide

shipment chain of condition

Tiles provide current condition of shipment

Interactive map displays

shipment routing

Reporting

Secure; FDA Compliant

Chain-of-Custody and Chain-of-Condition

Risk Management

Real-time monitoring

Proactive alerts and escalation

Appropriate lane optimization

Intervention Capable

Corrections; Redirections; Interceptions; Recharging alerts

Cloud-based and flexible

CryoportalTM can integrate with manufacturers, hub services, partner systems,

etc.

Amazon cloud-based archival and solution


Logistics Management Platform: CryoportalTM


Irvine, CA

Live view 24/7/365

Proactive support

Global intervention capability

Strategic operating centers

Covering 100+ countries

Global network of partners

FedEx® Deep Frozen

Shipping Solution

powered by Cryoport®

Partner of choice for:

Global Cryogenic Solution

Financial Overview


Revenue Trend – Pipeline for Growth

13April 2017

4-Year CAGR 72%

NASDAQ: CYRX

Summary

14

New and developing large market for

cryogenic logistics

Cellular therapies must have cryogenic logistics to deliver efficacy

Emerging regenerative medicines increasing demand for Cryoport

Regulatory requirements are expected to further increase demand

Impressive revenue growth driven by robust pipeline

4-year historical revenue CAGR of 72%

129 clinical trials drive revenue as trials progress; 18 in Phase III

First commercial biopharma client signed in 2016; two more in 2017

Advanced solutions create high barriers

to entry

Proven and validated by blue chip clients

Validated by and integrated with FedEx, UPS & DHL

Covering 100+ countries from operations centers in

California, The Netherlands and Singapore

Diversified and growing client

base

Novartis, Kite Pharma, Bristol-Myers Squibb,

bluebirdbio, Zoetis, Sanofi, Bellicum, Juno among

marquee clients

NASDAQ: CYRX April 2017

Management

Jerrell Shelton, CEO

Robert Stefanovich, CFO

Mark W. Sawicki, Ph.D., Chief Commercial Officer

Bret Bollinger, Vice President - Operations

Robert Copeland Jr., Vice President - Global Logistics

Thomas Heinzen, Vice President - Corporate Development

Board of directors

Jerrell Shelton, Chairman of the Board

Richard Berman, Lead Director

Robert Hariri, PhD, MD

Ramkumar Mandalam, Ph.D.

Edward Zecchini

15NASDAQ: CYRX April 2017

Management & Board of Directors

trusted by the life sciences industry

Documents